01—Abstract
Summary
Summary of the 10-K filed February 19, 2010. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories (ABT) filed its 2010 Form 10-K, reporting on its 2009 fiscal year.
The company operates across four key segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. A significant event during the reporting period was the acquisition of Advanced Medical Optics, Inc. (AMO) for approximately $1.4 billiona in February 2009, aimed at strengthening its vision care technologies portfolio. Additionally, Abbott announced its agreement to acquire Solvay's pharmaceuticals business for approximately $6.2 billion, which closed shortly after the reporting period ended in February 2010, significantly expanding its pharmaceutical offerings and global reach.
The company's financial performance in 2009 demonstrated resilience, with net sales increasing from the prior year. Key growth drivers included its flagship drug Humira®, which continued to show strong sales growth, and advancements in its Vascular Products segment with the launch of the Xience V drug-eluting stent.
However, the company also faced challenges, including generic competition impacting certain pharmaceutical products like Depakote® and Omnicef®, and ongoing litigation, notably a significant jury verdict related to Humira® patent infringement, which Abbott is appealing. The company's strategic focus remains on innovation, strategic acquisitions, and expanding its presence in emerging markets.
02—Key points
Key Highlights
- Abbott Laboratories reported robust performance in 2009, with net sales showing growth across its diversified health care segments.
- The company made a strategic acquisition of Advanced Medical Optics, Inc. (AMO) for approximately $1.4 billion, enhancing its position in vision care.
- Abbott announced its intention to acquire Solvay's pharmaceuticals business for approximately $6.2 billion, a transaction that closed shortly after the fiscal year, significantly bolstering its pharmaceutical segment.
- Humira®, a key pharmaceutical product, continued its strong sales trajectory, with significant contributions from both U.S. and international markets.
- The Vascular Products segment saw growth, driven by the Xience V drug-eluting stent, a market-leading product in the U.S.
- Generic competition negatively impacted sales of certain pharmaceutical products, notably Depakote® and Omnicef®.
- Abbott is actively managing significant legal proceedings, including a notable patent infringement case related to Humira®, with substantial damages awarded but currently under appeal.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2009, Abbott Laboratories kept $0.19.
- Revenue$30.76B100.0%
- Cost of revenue−$13.21B42.9%
- Gross profit$17.56B57.1%
- Operating costs−$11.32B36.8%
- Operating income$6.24B20.3%
- Interest, other & tax−$489.9M1.6%
- Net income$5.75B18.7%
Where FY2009 revenue went
$30.76B- Cost of revenue: $13.21B, 43% of revenue
- SG&A: $8.41B, 27% of revenue
- Net income: $5.75B, 19% of revenue
- Other operating costs: $2.91B, 9.5% of revenue
- Interest, other & tax: $489.9M, 1.6% of revenue
Kept 19% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2009filed February 19, 2010Financial Statements
FY2009 against FY2008
| Line item | FY2009FY2008 | Change |
|---|---|---|
| Revenue | $30.76B$29.53B | +4.2% |
| Cost of Revenue | $13.21B$12.61B | +4.7% |
| Gross Profit | $17.56B$16.92B | +3.8% |
| SG&A Expenses | $8.41B$8.44B | −0.4% |
| Operating Expenses | $24.53B$23.83B | +2.9% |
| Operating Income | $6.24B$5.69B | +9.5% |
| Interest Expense | $519.66M$528.47M | −1.7% |
| Net Income | $5.75B$4.88B | +17.7% |
| EPS (Basic) | $3.71$3.16 | +17.4% |
| EPS (Diluted) | $3.69$3.12 | +18.3% |
| Shares Outstanding (Basic) | 1.55B1.55B | +0.1% |
| Shares Outstanding (Diluted) | 1.56B1.56B | −0.4% |
05—Questions
Frequently Asked Questions
What were Abbott's major strategic moves or acquisitions in 2009?
In 2009, Abbott acquired Advanced Medical Optics, Inc. (AMO) for approximately $1.4 billion to strengthen its vision care business. The company also announced its agreement to acquire Solvay's pharmaceuticals business for approximately $6.2 billion, which closed in February 2010, significantly expanding its pharmaceutical portfolio and global presence.
Which products were key growth drivers for Abbott in 2009?
Humira®, a key pharmaceutical product, showed strong sales growth. The Xience V drug-eluting stent also performed well in the Vascular Products segment, becoming a market leader in the U.S.
What challenges did Abbott face in 2009?
Abbott faced challenges from generic competition, which led to declining sales for products like Depakote® and Omnicef®. The company was also involved in significant litigation, including a patent infringement case concerning Humira®, which resulted in a large jury award that is currently under appeal.
How did Abbott's international operations perform in 2009?
International sales represented approximately 50% of consolidated net sales. While international pharmaceutical sales showed growth, the stronger U.S. dollar had a negative impact on international sales in 2009, particularly in the Pharmaceutical and Diagnostic Products segments. Conversely, international pediatric nutritionals saw strong growth, especially in developing markets.
06—Continue